GALDERMA GRP AG
174,50€
+0,20 (+0,11%)
08.10.2026, 19:32:38 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® -297,39 -1,18% 24.806,97
- MDAX ® -430,86 -1,41% 30.112,41
- TecDAX ® -50,69 -1,24% 4.048,53
- E-STOXX 50 ® -91,94 -1,47% 6.180,29
- NASDAQ 100 -496,99 -1,59% 30.663,09
- HANG SENG -387,89 -1,61% 23.785,79
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 174,30€ | +0,11% |
| 1 Woche | 174,40€ | -0,06% |
| 1 Monat | 168,05€ | +3,72% |
| 6 Monate | 166,63€ | +4,60% |
| Lfd. Jahr (YTD) | -- | -- |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 174,50€ |
| Schluss Vortag | 174,30€ |
| Eröffnung | 174,05€ |
| Geld | 174,45€ |
| Brief | 175,20€ |
| Tages-Hoch | 174,80€ |
| Tages-Tief | 172,20€ |
| 52 Wochen-Hoch | 204,00€ |
| 52 Wochen-Tief | 149,00€ |
| Allzeit-Hoch | 204,00€ |
| Allzeit-Tief | 149,00€ |
Nachrichten
- BUSINESS WIRE: Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older - 08.10.2026, 07:00:07 Uhr
- BUSINESS WIRE: 30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation - 06.10.2026, 07:00:03 Uhr
- BUSINESS WIRE: EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - 30.09.2026, 07:00:02 Uhr
- BUSINESS WIRE: EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences - 23.09.2026, 07:00:06 Uhr
- BUSINESS WIRE: Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies - 21.09.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing - 16.09.2026, 07:00:01 Uhr
- BUSINESS WIRE: Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping - 11.08.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year - 23.07.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region - 20.07.2026, 07:00:03 Uhr
- BUSINESS WIRE: Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns - 07.07.2026, 07:00:06 Uhr
